+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neglected Tropical Disease Treatment Market by Disease Indication, Drug Type, Distribution Channel, End User, Route of Administration, Treatment Approach - Global Forecast to 2030- Product Image
Neglected Tropical Disease Treatment Market by Disease Indication, Drug Type, Distribution Channel, End User, Route of Administration, Treatment Approach - Global Forecast to 2030- Product Image
Sale

Neglected Tropical Disease Treatment Market by Disease Indication, Drug Type, Distribution Channel, End User, Route of Administration, Treatment Approach - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674161
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Neglected Tropical Disease Treatment Market grew from USD 6.40 billion in 2024 to USD 6.83 billion in 2025. It is expected to continue growing at a CAGR of 6.57%, reaching USD 9.38 billion by 2030.

A Comprehensive Overview of Current Challenges and Opportunities

Neglected tropical diseases impose a profound burden on vulnerable populations, often exacerbating cycles of poverty and limited access to healthcare infrastructure. Despite significant public health campaigns over the past decade, obstacles in drug availability, logistical distribution, and evolving pathogen resistance challenge eradication efforts. As global attention pivots toward universal health coverage, the treatment landscape for these diseases demands an integrated approach that spans innovation in therapeutics, strategic policy alignment, and sustainable financing models.

This executive summary distills the most critical developments shaping the neglected tropical disease treatment market. Through an analysis of policy shifts, tariff impacts, segmentation dynamics, regional variations, and company strategies, it provides a concise yet comprehensive view of current trends and future directions. Decision-makers in government agencies, non-governmental organizations, pharmaceutical firms, and global health alliances will gain clarity on where investments and interventions can produce the greatest public health returns. By framing actionable recommendations and highlighting methodological rigor, this summary serves as a cornerstone for informed strategic planning and collaborative initiatives.

How Recent Innovations and Collaborations Are Reshaping the Field

Emerging partnerships between philanthropic foundations and private-sector innovators have accelerated the development of new pharmacological agents targeting persistent pathogens. Simultaneously, digital tools such as geospatial mapping and telehealth platforms enhance real-time surveillance and remote treatment adherence. The advent of novel vector control technologies, including gene-silencing approaches and eco-friendly insecticides, signals a departure from traditional strategies that relied heavily on broad-spectrum chemical applications.

On the policy front, alignment between multilateral donors and endemic-country governments is reshaping procurement frameworks to prioritize equitable access. Innovative financing vehicles, such as social impact bonds, are increasingly used to de-risk outcomes-based programs. At the same time, the integration of community engagement models ensures that culturally relevant interventions gain traction and foster trust among affected populations.

These transformative shifts collectively bolster global capacity to interrupt transmission cycles. They underscore the imperative for stakeholders to pivot from siloed efforts toward holistic ecosystems of prevention, treatment, and monitoring that adapt swiftly to evolving epidemiological landscapes.

Assessing the Ripple Effects of Tariff Adjustments on Access and Supply

The introduction of new tariffs on pharmaceutical inputs and finished products has reverberated across supply chains and procurement budgets. Stakeholders from raw material suppliers to end-user programs have encountered pressures from increased import duties, which have driven up manufacturing costs and compressed margins for generic manufacturers. In response, many suppliers have shifted sourcing to lower-tariff jurisdictions, while others have pursued tariff-relief exemptions for essential medicines.

These adaptations have prompted a reconfiguration of regional distribution networks, as relief programs seek to minimize cost escalations and preserve treatment coverage. Procurement cycles now incorporate tariff impact assessments alongside traditional quality and compliance evaluations. As a result, tendering processes have become more complex and time-sensitive, demanding closer collaboration between finance teams and supply-chain managers.

Overarchingly, the cumulative effect of these policy changes underscores the necessity of resilient supply chains and the strategic anticipation of regulatory shifts. By embedding tariff risk management into long-term planning, stakeholders can safeguard both continuity of care and fiscal sustainability.

Unpacking the Six-Dimensional Market Segmentation Framework

Analysis of treatment demand by disease indication reveals that dengue interventions continue to command significant programmatic focus, while efforts to eliminate lymphatic filariasis and onchocerciasis maintain momentum through mass drug initiatives. Schistosomiasis remains a priority in regions where waterborne transmission persists, and trachoma programs leverage integrated eye care campaigns to achieve community-wide impact. Examining drug type usage highlights how anthelmintics such as albendazole, ivermectin, and mebendazole form the backbone of deworming protocols, while antibiotics including azithromycin and doxycycline play critical roles in trachoma control. Antiprotozoals like meglumine, pentamidine, and suramin are deployed strategically where protozoan infections pose the greatest threats, complemented by targeted insecticide applications and antiarthropodal agents.

Distribution channel insights indicate that government programs underpin large-scale mass drug administration, hospital pharmacy networks manage treatment regimens for severe cases, and NGO distribution channels extend reach into remote communities, with retail pharmacies serving as accessible points of replenishment. End-user analysis underscores the vital roles of clinics and community health centers in routine care, hospitals in advanced case management, and mobile camps in delivering rapid response during outbreak scenarios. Evaluating routes of administration shows oral formulations dominate due to ease of deployment and patient compliance, with parenteral and topical options reserved for specific indications and severe manifestations. Finally, contrasting mass drug administration against targeted therapy approaches reveals that while broad coverage accelerates community-level disease reduction, precision interventions optimize resources for high-risk populations.

Regional Dynamics Driving Tailored Treatment Strategies

In the Americas, collaborative efforts between regional public health organizations and local manufacturing hubs have streamlined the distribution of essential medicines, while innovative public-private partnerships are funding community-based surveillance and treatment programs. Within Europe, Middle East & Africa, donor fatigue in some high-income regions contrasts with heightened investment by emerging philanthropic entities, supporting integrated vector management and capacity building for endemic-country laboratories. The Asia-Pacific region showcases rapid adoption of digital diagnostics and mobile health platforms, enabling decentralized screening and adherence monitoring in geographically dispersed populations.

Across these regions, the harmonization of regulatory standards and pooled procurement mechanisms strengthens supply-chain resilience and drives economies of scale. Meanwhile, regional research consortia are fostering cross-border clinical trials and knowledge exchange, accelerating the translation of novel therapies into practice. Recognizing these differentiated dynamics allows stakeholders to tailor strategies that reflect each region’s funding landscape, infrastructural maturity, and disease burden profiles.

Major Players Shaping the Competitive Environment

Leading pharmaceutical companies have intensified R&D investments in next-generation anthelmintics and vector control agents, diversifying their portfolios through strategic alliances with biotech innovators. Several organizations have forged licensing agreements to expand access to generic formulations of ivermectin and albendazole, bolstering affordability in low-income markets. At the same time, non-profit consortia are collaborating with core industry players to establish manufacturing facilities in endemic regions, enhancing local production capacity and fostering technology transfer.

Meanwhile, emerging specialists in drug delivery systems are piloting microencapsulation techniques to improve shelf stability and permit targeted release of active ingredients. Diagnostics firms are integrating artificial intelligence into point-of-care tools to expedite case identification and streamline treatment initiation. By leveraging cross-sector partnerships, these companies are scaling up distribution networks and refining value propositions that align with public health objectives. Collectively, their actions underscore a shift toward shared-value models that reconcile commercial viability with social impact.

Actionable Strategies to Strengthen Market Resilience and Impact

Industry leaders should prioritize the establishment of integrated risk management frameworks that encompass tariff fluctuations, regulatory shifts, and supply-chain disruptions. Strengthening partnerships with endemic-country health authorities and community stakeholders will enhance program responsiveness and reinforce local ownership of treatment initiatives. Investing in digital health solutions that combine geospatial analytics with remote monitoring can accelerate case detection and optimize resource allocation.

Simultaneously, companies and organizations should explore innovative financing mechanisms, including social impact bonds and blended-finance structures, to diversify funding streams and mitigate donor concentration risks. Pursuing local manufacturing collaborations will reduce lead times, build regional capacity, and support more sustainable pricing models. Emphasizing adaptive R&D pipelines that incorporate real-world data and community feedback loops will ensure that therapeutic innovations remain relevant and effective against evolving disease patterns.

Methodological Rigor Underpinning the Analysis

This analysis synthesizes qualitative interviews with global health experts, procurement officers, and clinical researchers, alongside a thorough review of regulatory filings, policy documents, and peer-reviewed publications. Market segmentation data derive from validated public health databases and proprietary treatment registries, ensuring comprehensive coverage across disease indications, drug types, distribution channels, end users, routes of administration, and treatment approaches.

Regional insights are informed by structured consultations with in-country epidemiologists and supply-chain specialists, while company profiles draw on financial disclosures, partnership announcements, and pipeline reports. Tariff impact modeling integrates historical customs data and scenario analysis to capture policy uncertainties. All findings undergo triangulation through cross-verification with independent third-party sources, maintaining methodological rigor and reliability. This multi-method approach delivers a balanced perspective that combines macro-level trends with operational granularity.

Synthesizing Insights to Chart the Path Forward

As the fight against neglected tropical diseases intensifies, stakeholders face both unprecedented opportunities and persistent challenges. The convergence of scientific innovation, digital health advancements, and policy reforms provides a fertile ground for transformative progress. However, managing external pressures such as tariff adjustments and supply-chain disruptions requires vigilant planning and adaptive strategies.

Ultimately, achieving sustainable elimination hinges on collaborative ecosystems that integrate government leadership, private-sector innovation, and community engagement. By aligning investments with data-driven insights and regional priorities, decision-makers can optimize resource utilization and amplify health outcomes. This executive summary offers a strategic compass to navigate the complex terrain, laying the groundwork for concerted action and enduring impact.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Disease Indication
    • Dengue
    • Lymphatic Filariasis
    • Onchocerciasis
    • Schistosomiasis
    • Trachoma
  • Drug Type
    • Anthelmintics
      • Albendazole
      • Ivermectin
      • Mebendazole
    • Antiarthropodals
    • Antibiotics
      • Azithromycin
      • Doxycycline
    • Antiprotozoals
      • Meglumine
      • Pentamidine
      • Suramin
    • Insecticides
  • Distribution Channel
    • Government Programs
    • Hospital Pharmacy
    • NGO Distribution
    • Retail Pharmacy
  • End User
    • Clinics
    • Community Health Centers
    • Hospitals
    • Mobile Camps
  • Route Of Administration
    • Oral
    • Parenteral
    • Topical
  • Treatment Approach
    • Mass Drug Administration
    • Targeted Therapy
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Sanofi S.A.
  • Johnson & Johnson
  • Novartis AG
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • Eisai Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Neglected Tropical Disease Treatment Market, by Disease Indication
8.1. Introduction
8.2. Dengue
8.3. Lymphatic Filariasis
8.4. Onchocerciasis
8.5. Schistosomiasis
8.6. Trachoma
9. Neglected Tropical Disease Treatment Market, by Drug Type
9.1. Introduction
9.2. Anthelmintics
9.2.1. Albendazole
9.2.2. Ivermectin
9.2.3. Mebendazole
9.3. Antiarthropodals
9.4. Antibiotics
9.4.1. Azithromycin
9.4.2. Doxycycline
9.5. Antiprotozoals
9.5.1. Meglumine
9.5.2. Pentamidine
9.5.3. Suramin
9.6. Insecticides
10. Neglected Tropical Disease Treatment Market, by Distribution Channel
10.1. Introduction
10.2. Government Programs
10.3. Hospital Pharmacy
10.4. NGO Distribution
10.5. Retail Pharmacy
11. Neglected Tropical Disease Treatment Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Community Health Centers
11.4. Hospitals
11.5. Mobile Camps
12. Neglected Tropical Disease Treatment Market, by Route of Administration
12.1. Introduction
12.2. Oral
12.3. Parenteral
12.4. Topical
13. Neglected Tropical Disease Treatment Market, by Treatment Approach
13.1. Introduction
13.2. Mass Drug Administration
13.3. Targeted Therapy
14. Americas Neglected Tropical Disease Treatment Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Neglected Tropical Disease Treatment Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Neglected Tropical Disease Treatment Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. GlaxoSmithKline plc
17.3.2. Merck & Co., Inc.
17.3.3. Merck KGaA
17.3.4. Pfizer Inc.
17.3.5. Sanofi S.A.
17.3.6. Johnson & Johnson
17.3.7. Novartis AG
17.3.8. Bayer AG
17.3.9. Takeda Pharmaceutical Company Limited
17.3.10. Eisai Co., Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. NEGLECTED TROPICAL DISEASE TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. NEGLECTED TROPICAL DISEASE TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. NEGLECTED TROPICAL DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2024 VS 2030 (%)
FIGURE 18. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. NEGLECTED TROPICAL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. NEGLECTED TROPICAL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. NEGLECTED TROPICAL DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DENGUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY LYMPHATIC FILARIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ONCHOCERCIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TRACHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ALBENDAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY IVERMECTIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEBENDAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIARTHROPODALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MEGLUMINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PENTAMIDINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY SURAMIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY INSECTICIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY GOVERNMENT PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY NGO DISTRIBUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MOBILE CAMPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY MASS DRUG ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 66. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 67. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 68. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 69. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 70. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 71. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. CANADA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 75. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 76. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 79. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. MEXICO NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 121. GERMANY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 122. GERMANY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 123. GERMANY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 124. GERMANY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 125. GERMANY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 126. GERMANY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. GERMANY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. GERMANY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. GERMANY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 130. FRANCE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 131. FRANCE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 132. FRANCE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 133. FRANCE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 134. FRANCE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 135. FRANCE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. FRANCE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. FRANCE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. FRANCE NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 148. ITALY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 149. ITALY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 150. ITALY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 151. ITALY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 152. ITALY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 153. ITALY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. ITALY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. ITALY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. ITALY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 157. SPAIN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 158. SPAIN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 159. SPAIN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 160. SPAIN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 161. SPAIN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 162. SPAIN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. SPAIN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. SPAIN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. SPAIN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. UNITED ARAB EMIRATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. UNITED ARAB EMIRATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. UNITED ARAB EMIRATES NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. SAUDI ARABIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. SAUDI ARABIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. SOUTH AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. SOUTH AFRICA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 193. DENMARK NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 194. DENMARK NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 195. DENMARK NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 196. DENMARK NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 197. DENMARK NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 198. DENMARK NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. DENMARK NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. DENMARK NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. DENMARK NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. NETHERLANDS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. NETHERLANDS NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 211. QATAR NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 212. QATAR NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 213. QATAR NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 214. QATAR NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 215. QATAR NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 216. QATAR NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. QATAR NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. QATAR NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. QATAR NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 220. FINLAND NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 221. FINLAND NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 222. FINLAND NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 223. FINLAND NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 224. FINLAND NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 225. FINLAND NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. FINLAND NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. FINLAND NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. FINLAND NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. SWEDEN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. SWEDEN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. SWEDEN NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. NIGERIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. NIGERIA NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 247. EGYPT NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 248. EGYPT NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 249. EGYPT NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 250. EGYPT NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 251. EGYPT NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 252. EGYPT NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. EGYPT NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. EGYPT NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. EGYPT NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 256. TURKEY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 257. TURKEY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 258. TURKEY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 259. TURKEY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 260. TURKEY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 261. TURKEY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. TURKEY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. TURKEY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. TURKEY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 274. NORWAY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 275. NORWAY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 276. NORWAY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 277. NORWAY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 278. NORWAY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIPROTOZOALS, 2018-2030 (USD MILLION)
TABLE 279. NORWAY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. NORWAY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. NORWAY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. NORWAY NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY TREATMENT APPROACH, 2018-2030 (USD MILLION)
TABLE 283. POLAND NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 284. POLAND NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 285. POLAND NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTHELMINTICS, 2018-2030 (USD MILLION)
TABLE 286. POLAND NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 287. POLAND NEGLECTED TROPICAL DISEASE TREATMENT MARKET SIZE, BY AN

Companies Mentioned

The companies profiled in this Neglected Tropical Disease Treatment market report include:
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Sanofi S.A.
  • Johnson & Johnson
  • Novartis AG
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • Eisai Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.83 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.38 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Neglected Tropical Diseases Diagnosis Market by Technology, Disease Type, End User, Application, Sample Type - Global Forecast to 2030 - Product Image

Neglected Tropical Diseases Diagnosis Market by Technology, Disease Type, End User, Application, Sample Type - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Neglected Tropical Disease Treatment Market Size, Share & Trends Analysis Report by Disease (Dengue, Rabies, Trachoma, Chagas Disease), Product (Drugs, Vaccines), Region, and Segment Forecasts, 2024-2030 - Product Image

Neglected Tropical Disease Treatment Market Size, Share & Trends Analysis Report by Disease (Dengue, Rabies, Trachoma, Chagas Disease), Product (Drugs, Vaccines), Region, and Segment Forecasts, 2024-2030

  • Report
  • 90 Pages
  • Global
From
Neglected Tropical Diseases Diagnosis Market Size, Share & Trends Analysis Report By Disease, By Diagnostic Method, By Service Type, By End-use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Neglected Tropical Diseases Diagnosis Market Size, Share & Trends Analysis Report By Disease, By Diagnostic Method, By Service Type, By End-use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Neglected Tropical Disease Treatment - Global Strategic Business Report - Product Image

Neglected Tropical Disease Treatment - Global Strategic Business Report

  • Report
  • 294 Pages
  • Global
From
Neglected Tropical Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Neglected Tropical Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.